Recursion Pharmaceuticals
RXRX
RXRX
158 hedge funds and large institutions have $841M invested in Recursion Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 32 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
158
Holders Change
+14
Holders Change %
+9.72%
% of All Funds
2.53%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.08%
New
29
Increased
55
Reduced
32
Closed
14
Calls
$633K
Puts
$383K
Net Calls
+$250K
Net Calls Change
+$156K
Top Buyers
| 1 |
1
Vanguard Group
Malvern,
Pennsylvania
|
$72.9M |
| 2 |
2
Marshall Wace
London,
United Kingdom
|
$3.43M |
| 3 |
3
Dimensional Fund Advisors
Austin,
Texas
|
$4.65M |
| 4 |
AIM
4
ARK Investment Management
St. Petersburg,
Florida
|
$23.9M |
| 5 |
5
Citigroup
New York
|
$4.59M |
